Restricting Patent Challenges Will Harm Small Businesses

May 26, 2015
1 min read

After building momentum for weeks, congressional action on patent reform legislation is beginning to slow. The Senate Judiciary Committee has twice postponed markup of the bi-partisan PATENT Act in recent weeks. Reportedly, one reason behind the pause is a push by the pharmaceutical industry to include amendments that would limit the Patent and Trademark Office’s (PTO) authority to reevaluate the validity of issued patents at the request of third-parties that haven’t themselves been accused of infringement.

Recent Posts

See All

Diverse Coalition of Industries Endorses Bipartisan CLEAR Act to Reform Patent Litigation and Protect Main Street Businesses

WASHINGTON, D.C. – Today, United for Patent Reform (UFPR), whose member companies represent over 90 million U.S. employees, announced widespread industry support for the Customer Legal Ease and Relie

Former Members of Congress Pen Letter to USPTO Opposing IPR Rule

Today, over a dozen former members of Congress, who helped pass the America Invents Act, raised the alarm on U.S. Patent and Trademark Office's proposed IPR rule. Click here to view the letter.

UFPR Submits Comment to USPTO on Proposed Rule Impacting IPR

United for Patent Reform (UFPR) submitted a comment to the U.S. Patent and Trademark Office strongly opposing the October 17, 2025 Notice of Proposed Rulemaking (NPRM) that would cut off access to the